Company news: GSK, Salix

Share this article:
GlaxoSmithKline returned marketing rights on epilepsy drug Horizant to XenoPort effective April 30, 2013. GSK agreed to buy $20 million of common stock in the company as part of the deal, and took a $165 million one-time charge for the transaction.

Salix Pharmaceuticals reported revenues up 27% to $185 million for the third quarter over the same period last year. Nine-month revenues were up 39% on strong sales of Xifaxan, which pulled in $367 million in the first three quarters of the year – up 43% over last year.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.